Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 22: ONTARGET - secondary end points Abb. 23: TRANSCEND - Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant Subjects with Cardiovascular Disease Abb. 24: TRANSCEND - background Aktuelles Bild - Abb. 25: TRANSCEND - objectives Abb. 26: TRANSCEND - patient profile Abb. 27: TRANSCEND - study design Abb. 28: TRANSCEND - study design Zum letzten Bild
Abbildung 25: TRANSCEND - objectives
TRANSCEND will assess the efficacy of telmisartan 80 mg in reducing cardiovascular morbidity and mortality in patients who are at high cardiovascular risk but are unable to tolerate ACE inhibitor treatment. It should provide evidence that ARB therapy is beneficial in this patient population; this is already assumed by many physicians.
 
TRANSCEND - objectives
Vorheriges Bild Nächstes Bild   


Abbildung 25: TRANSCEND - objectives
TRANSCEND will assess the efficacy of telmisartan 80 mg in reducing cardiovascular morbidity and mortality in patients who are at high cardiovascular risk but are unable to tolerate ACE inhibitor treatment. It should provide evidence that ARB therapy is beneficial in this patient population; this is already assumed by many physicians.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung